SCHEMBL6908655

SCHEMBL6908655

O=C(CCNC(=O)OCc1ccccc1)NCCS(=O)(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
LMNA P02545 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TGM2 P21980 1/20 0.51
L3MBTL1 Q9Y468 4/20 0.49
KEAP1 Q14145 2/20 0.49
NFE2L2 Q16236 2/20 0.49
GAA P10253 1/20 0.48
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
PRSS1 P07477 1/20 0.47
TPSAB1 Q15661 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6051915 0.99 HTT (0.56) HTTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4061201 0.92 LMNA (0.65) HTTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL3798700 0.90 LMNA (0.63) HTTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL14414733 0.88 HTT (0.56) HTTMEN1KMT2ALMNASMN1; SMN2
Zinc Ion SCHEMBL6912263 0.87 HTT (0.54) HTTMEN1KMT2ALMNASMN1; SMN2
Sulfuric Acid SCHEMBL6913701 0.87 HTT (0.57) HTTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL7514786 0.85 HTT (0.73) HTTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4173649 0.83 HTT (0.62) HTTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL917878 0.83 HTT (0.67) HTTLMNASMN1; SMN2TGM2L3MBTL1
SCHEMBL3309927 0.83 HTT (0.67) HTTLMNASMN1; SMN2TGM2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9655870-B2 Homeopathic drug composition and methods of use thereof FINDCURE.ORG (US) 2017-05-23 US disclosed
US-9655870-B2 Homeopathic drug composition and methods of use thereof FINDCURE.ORG (US) 2017-05-23 US disclosed
US-20070141169-A1 Homeopathic drug composition and methods of use thereof TAUB FLOYD 2007-06-21 US disclosed
US-20070141169-A1 Homeopathic drug composition and methods of use thereof TAUB FLOYD 2007-06-21 US disclosed
US-6762174-B1 BETA-ALETHINE WITH MELPHALAN OR CYCLOPHOSPHAMIDE; PREVENTS CLINICAL APPEARANCE OF A NEOPLASTIC OR PRE-NEOPLASTIC CONDITION; IMMUNOMODULATION; ENHANCING CELL GROWTH, VITALITY, DIFFERENTIATION; ANTISENESCENCE DOVETAIL TECHNOLOGIES, INC. 2004-07-13 US disclosed
US-6498150-B2 USEFUL IN ENHANCING VACCINATION, INCREASING SYNTHESIS AND FUNCTION OF BLOOD CELL COMPONENTS, AND ENHANCING ANTITUMOR EFFECTS DOVETAIL TECHNOLOGIES, INC. 2002-12-24 US disclosed
US-6451853-B1 Small molecules that elicit a polarized Th1 response and for modulation of cellular immunity DOVETAIL TECHNOLOGIES, INC 2002-09-17 US disclosed
US-20020035118-A1 LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS DOVETAIL TECHNOLOGIES INC. 2002-03-21 US disclosed
US-6007819-A Methods of inducing immunity using low molecular weight immune stimulants DOVETAIL TECHNOLOGIES, INC. (US) 1999-12-28 US disclosed
WO-1999042099-A1 LOW MOLECULAR WEIGHT COMPOUNDS ADMINISTERED TOGETHER WITH ANTI-CANCER AGENTS TO TREAT CANCER AND PHARMACEUTICAL COMPOSITIONS THEREOF DOVETAIL TECHNOLOGIES INC. (US) 1999-08-26 WO disclosed
WO-1997014306-A1 LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS DOVETAIL TECHNOLOGIES, INC. (US) 1997-04-24 WO disclosed
US-5578313-A Therapeutic use of vitaletheine modulators in neoplasia THE UNIVERSITY OF NEW MEXICO (US) 1996-11-26 US disclosed
US-4218404-A HYPOGLYCEMIC AGENTS CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1980-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035118-A1 LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS ACP1, CD14, HPGDS HTT 4286/4885MEN1 982/4885KMT2A 2729/4885
US-20070141169-A1 Homeopathic drug composition and methods of use thereof S100A11, PTGER3, CLN6 HTT 46/4885MEN1 1894/4885KMT2A 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.